Foghorn Therapeutics (FHTX) Amortizatization of Intangibles (2020 - 2026)
Foghorn Therapeutics' (FHTX) quarterly Amortizatization of Intangibles came in at $388000.0 in Q1 2026, down 52.57% year-on-year from $818000.0 in Q1 2025, and up 26.8% quarter-over-quarter from $306000.0 in Q4 2025.
Foghorn Therapeutics (FHTX) Amortizatization of Intangibles (2020 - 2026) Analysis & Trends
Foghorn Therapeutics' Amortizatization of Intangibles history runs 7 years deep, the most recent figure standing at $388000.0 for Q1 2026.
- On a quarterly basis, Amortizatization of Intangibles fell 52.57% year-over-year to $388000.0 in Q1 2026; TTM through Mar 2026 was $1.5 million, a 69.33% decrease from a year earlier, with the FY2025 full-year figure at $1.9 million, down 58.25% from the prior year.
- Amortizatization of Intangibles rose to $388000.0 in Q1 2026 per FHTX's latest filing, from $306000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $1.8 million in Q3 2024 and bottomed at -$38000.0 in Q1 2022.
- The 5-year median for Amortizatization of Intangibles is $554000.0 (2024), against an average of $639588.2.
- Biggest YoY gain for Amortizatization of Intangibles was 6540.0% in 2022; the steepest drop was 392.31% in 2022.
- Year by year, Amortizatization of Intangibles stood at $574000.0 in 2022, then slipped by 13.76% to $495000.0 in 2023, then surged by 216.97% to $1.6 million in 2024, then tumbled by 80.5% to $306000.0 in 2025, then increased by 26.8% to $388000.0 in 2026.
- Per Business Quant, the three latest FHTX Amortizatization of Intangibles figures stand at $388000.0 (Q1 2026), $306000.0 (Q4 2025), and $356000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 3.22 Mn |
| 10 | Foghorn Therapeutics | 362.65 Mn | 273.74 Mn | - | 388,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 388,000.00 |
| Mar 31, 2026 | 388,000.00 |
| Dec 31, 2025 | 306,000.00 |
| Dec 31, 2025 | 306,000.00 |
| Sep 30, 2025 | 356,000.00 |
| Sep 30, 2025 | 356,000.00 |
| Jun 30, 2025 | 446,000.00 |
| Jun 30, 2025 | 446,000.00 |
| Mar 31, 2025 | 818,000.00 |
| Mar 31, 2025 | 818,000.00 |
| Dec 31, 2024 | 1.57 Mn |
| Dec 31, 2024 | 1.57 Mn |
| Sep 30, 2024 | 1.79 Mn |
| Sep 30, 2024 | 1.79 Mn |
| Jun 30, 2024 | 705,000.00 |
| Jun 30, 2024 | 705,000.00 |
| Mar 31, 2024 | 554,000.00 |
| Mar 31, 2024 | 554,000.00 |
| Dec 31, 2023 | 495,000.00 |
| Dec 31, 2023 | 495,000.00 |